Pegunigalsidase alfa, PEGylated α-galactosidase-A enzyme in development for the treatment of Fabry disease, shows correlation between renal GB3 inclusion clearance and reduction of plasma Lyso-GB3

Autor:	Sari Alon, Gustavo Maegawa, Simeon Boyd, Mohamed G. Atta, Myrl Holida, Robert B. Colvin, Ozlem Goker-Alpan, Kathy Nicholls, Ahmad Tuffaha, Derlis Gonzales, Derralynn Hughes, J. Charles Jennette, Pilar Giraldo, Mali Szlaifer, Raul Chertkoff, Einat Brill-Almon, Raphael Schiffmann, Laura Barisoni
Rok vydání:	2020
Předmět:	chemistry.chemical_classification medicine.medical_specialty Chemistry Endocrinology Diabetes and Metabolism Lyso gb3 medicine.disease Biochemistry Fabry disease Endocrinology α galactosidase a Enzyme Internal medicine Genetics medicine Molecular Biology
Zdroj:	Molecular Genetics and Metabolism. 129:S76-S77
ISSN:	1096-7192
DOI:	10.1016/j.ymgme.2019.11.185
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::51f1531a46901b74095174e7ff084991 https://doi.org/10.1016/j.ymgme.2019.11.185 Zobrazit plný text záznamu Full Text from ScienceDirect